Revolutionizing R-R cHL Treatment: Affimed’s Acimtamig and AlloNK Combination Proves Safe and Effective for Relapsed/Refractory Classical Hodgkin Lymphoma Patients
MANNHEIM, Germany, Dec. 08, 2024 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD)
Affimed, a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the presentation of data in a poster session at the 66th ASH Annual Meeting and Exposition. The dataset includes 22 patients from the run-in phase of the LuminICE-203 (AFM13-203) phase 2 open-label, multicenter, multi-cohort study. The trial evaluates the safety and efficacy of the combination of acimtamig (AFM13) with Artiva Biotherapeutics’ allogeneic NK cell AlloNK® in patients with R/R cHL.
This groundbreaking study marks a significant advancement in the treatment of relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients. The combination of acimtamig and AlloNK has demonstrated both safety and efficacy in a cohort of 22 patients, showcasing promising results and giving hope to those battling this aggressive form of cancer.
Impact on Individuals:
For individuals diagnosed with relapsed or refractory classical Hodgkin lymphoma, the news of Affimed’s successful combination treatment offers a ray of hope. This breakthrough therapy provides new possibilities for patients who may have exhausted all other treatment options. The safety and effectiveness demonstrated in the study present a potential lifeline for those facing the challenges of R/R cHL, offering renewed optimism and a chance for improved outcomes in their battle against cancer.
Impact on the World:
The implications of Affimed’s groundbreaking combination treatment extend beyond individual patients to the broader landscape of oncology and immuno-oncology. The successful results of this study pave the way for future advancements in the treatment of classical Hodgkin lymphoma, setting a new standard for innovative therapies in the field. The collaboration between Affimed and Artiva Biotherapeutics highlights the potential of combining different modalities to deliver more effective and targeted treatments for cancer, ultimately reshaping the way we approach and combat this disease on a global scale.
Conclusion:
The announcement of Affimed’s successful combination treatment for relapsed/refractory classical Hodgkin lymphoma marks a pivotal moment in the field of immuno-oncology. With promising results and a commitment to improving outcomes for patients, this innovative approach has the potential to revolutionize the treatment landscape for R/R cHL. As we look towards the future of cancer therapy, collaborations like this offer hope and inspiration for both individuals fighting the disease and the world at large, signaling a new era of possibilities in the fight against cancer.
